In a recent article for Healthcare Business Today, Bradley Nelson, Pharm.D., Senior Director of Clinical Services at RxBenefits, highlights the growing concern regarding off-label use of GLP-1 medications. Originally meant for type 2 diabetes treatment, these drugs are increasingly prescribed for weight loss, leading to safety issues, limited access to medications for those in need, and higher healthcare costs.
To address these risks, Nelson suggests plan sponsors implement utilization management solutions, such as formulary management, prior authorization programs, and quantity limits. These measures protect members’ well-being while managing pharmacy spending effectively.
To gain insights into mitigating risks associated with off-label GLP-1 use and ensuring better healthcare outcomes, read the full article on Healthcare Business Today.
